Skip to main content
Erschienen in: Familial Cancer 1/2011

01.03.2011

A new mutation of BRCA2 gene in an Italian healthy woman with familial breast cancer history

verfasst von: Maurizio Pisanò, Valeria Mezzolla, Maria Maddalena Galante, Giovanni Alemanno, Corrado Manca, Vito Lorusso, Antonio Malvasi, Andrea Tinelli

Erschienen in: Familial Cancer | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Heterozygous germ line mutations in the Breast CAncer1 (BRCA1) and BRCA2 genes can lead to a high risk of breast and ovarian cancer, in addition to a significantly increased susceptibility of pancreatic, prostate and male breast cancer. The BRCA2 belongs to the tumor suppressor gene family and the protein encoded by this gene is involved in the repair of chromosomal damage, with an important role in the error-free repair of DNA double strand breaks. After complete sequencing of coding regions and splice junctions of both genes, in a family with breast cancer history, a non previously reported heterozygous mutation in BRCA2 was detected and studied in an Italian healthy female. The direct sequencing disclosed, on exon 15, an insertion (7525_7526insT). The frame shift mutation of BRCA2 causes a disruption of the translational reading frame, resulting in a stop codon 29 amino acids downstream, in the 2538 position of the BRCA2 protein. The mutated allele codifies a truncated protein, lacking the two putative nuclear localization signals (NLSs) that reside within the extreme C-terminal domain of BRCA2. Since this mutant protein not performs a translocation into the nucleus, it is fully non-functional.
Literatur
1.
Zurück zum Zitat Tinelli A, Malvasi A, Leo G, Vergara D, Pisanò M, Ciccarese M, Chiuri VE, Lorusso V (2010) Hereditary ovarian cancers: from BRCA mutations to clinical management a modern appraisal. Cancer Metastasis Rev 29(2):339–350CrossRefPubMed Tinelli A, Malvasi A, Leo G, Vergara D, Pisanò M, Ciccarese M, Chiuri VE, Lorusso V (2010) Hereditary ovarian cancers: from BRCA mutations to clinical management a modern appraisal. Cancer Metastasis Rev 29(2):339–350CrossRefPubMed
2.
Zurück zum Zitat Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40:17–22CrossRefPubMed Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40:17–22CrossRefPubMed
3.
Zurück zum Zitat Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, Langholz B, Bernstein L, Olsen JH, Lynch CF, Anton-Culver H, Capanu M, Liang X, Hummer AJ, Sima C, Bernstein JL (2008) Variation of breast cancer risk among BRCA1/2 carriers. J Am Med Assoc 299:194–201CrossRef Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, Langholz B, Bernstein L, Olsen JH, Lynch CF, Anton-Culver H, Capanu M, Liang X, Hummer AJ, Sima C, Bernstein JL (2008) Variation of breast cancer risk among BRCA1/2 carriers. J Am Med Assoc 299:194–201CrossRef
4.
Zurück zum Zitat Xu X, Qiao W, Linke SP, Cao L, Li WM, Furth PA, Harris CC, Deng CX (2001) Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 28:266–271CrossRefPubMed Xu X, Qiao W, Linke SP, Cao L, Li WM, Furth PA, Harris CC, Deng CX (2001) Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 28:266–271CrossRefPubMed
5.
Zurück zum Zitat Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A (2001) Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29:418–425CrossRefPubMed Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A (2001) Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29:418–425CrossRefPubMed
6.
Zurück zum Zitat Yang H, Jeffrey PD, Miller J, Kinnucan E, Sun Y, Thomav NH, Zheng N, Chen PL, Lee WH, Pavletich NP (2002) BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 297:1837–1848CrossRefPubMed Yang H, Jeffrey PD, Miller J, Kinnucan E, Sun Y, Thomav NH, Zheng N, Chen PL, Lee WH, Pavletich NP (2002) BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 297:1837–1848CrossRefPubMed
7.
Zurück zum Zitat Esashi F, Christ N, Gannon J, Liu Y, Hunt T, Jasin M, West SC (2005) CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 434:598–604CrossRefPubMed Esashi F, Christ N, Gannon J, Liu Y, Hunt T, Jasin M, West SC (2005) CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 434:598–604CrossRefPubMed
8.
Zurück zum Zitat Galkin VE, Esashi F, Yu X, Yang S, West SC, Egelman EH (2005) BRCA2 BRC motifs bind RAD51-DNA filaments. Proc Natl Acad Sci 102(24):8537–8542CrossRefPubMed Galkin VE, Esashi F, Yu X, Yang S, West SC, Egelman EH (2005) BRCA2 BRC motifs bind RAD51-DNA filaments. Proc Natl Acad Sci 102(24):8537–8542CrossRefPubMed
9.
Zurück zum Zitat Moynahan ME, Pierce AJ, Jasin M (2001) BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 7(2):263–272CrossRefPubMed Moynahan ME, Pierce AJ, Jasin M (2001) BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 7(2):263–272CrossRefPubMed
10.
Zurück zum Zitat Tutt A, Gabriel A, Bertwistle D, Connor F, Paterson H, Peacock J, Ross G, Ashworth A (1999) Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr Biol 9:1107–1110CrossRefPubMed Tutt A, Gabriel A, Bertwistle D, Connor F, Paterson H, Peacock J, Ross G, Ashworth A (1999) Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr Biol 9:1107–1110CrossRefPubMed
11.
Zurück zum Zitat Daniels MJ, Wang Y, Lee M, Venkitaraman AR (2004) Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 306(5697):876–879CrossRefPubMed Daniels MJ, Wang Y, Lee M, Venkitaraman AR (2004) Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 306(5697):876–879CrossRefPubMed
12.
Zurück zum Zitat Van Golen K, Milliron K, Davies S, Merajver SD (1999) BRCA-associated cancer risk: molecular biology and clinical practice. J Lab Clin Med 134(1):11–18CrossRefPubMed Van Golen K, Milliron K, Davies S, Merajver SD (1999) BRCA-associated cancer risk: molecular biology and clinical practice. J Lab Clin Med 134(1):11–18CrossRefPubMed
13.
Zurück zum Zitat Chen X, Truong TT, Weaver J, Bove BA, Cattie K, Armstrong BA, Daly MB, Godwin AK (2006) Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression. Hum Mutat 27:427–435CrossRefPubMed Chen X, Truong TT, Weaver J, Bove BA, Cattie K, Armstrong BA, Daly MB, Godwin AK (2006) Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression. Hum Mutat 27:427–435CrossRefPubMed
14.
Zurück zum Zitat Farrugia DJ, Agarwal MK, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Wadum L, Johnson K, Mentlick J, Tavtigian SV, Goldgar DE, Couch FJ (2008) Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res 68(9):3523–3531CrossRefPubMed Farrugia DJ, Agarwal MK, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Wadum L, Johnson K, Mentlick J, Tavtigian SV, Goldgar DE, Couch FJ (2008) Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res 68(9):3523–3531CrossRefPubMed
15.
Zurück zum Zitat Hay T, Clarke AR (2005) DNA damage hypersensitivity in cells lacking BRCA2: a review of in vitro and in vivo data. Biochem Soc Trans 33(Pt 4):715–717PubMed Hay T, Clarke AR (2005) DNA damage hypersensitivity in cells lacking BRCA2: a review of in vitro and in vivo data. Biochem Soc Trans 33(Pt 4):715–717PubMed
16.
Zurück zum Zitat Edwards S, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451(7182):1111–1115CrossRefPubMed Edwards S, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451(7182):1111–1115CrossRefPubMed
17.
Zurück zum Zitat Iglehart JD, Silver DP (2009) Synthetic lethality—a new direction in cancer-drug development. N Engl J Med 361(2):189–191CrossRefPubMed Iglehart JD, Silver DP (2009) Synthetic lethality—a new direction in cancer-drug development. N Engl J Med 361(2):189–191CrossRefPubMed
18.
Zurück zum Zitat Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JHM, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. New Engl J Med 361(2):123–134CrossRefPubMed Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JHM, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. New Engl J Med 361(2):123–134CrossRefPubMed
19.
Zurück zum Zitat Spain BH, Larson CJ, Shihabuddin LS, Gage FH, Verma IM (1999) Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations. Proc Natl Acad Sci USA 96:13920–13925CrossRefPubMed Spain BH, Larson CJ, Shihabuddin LS, Gage FH, Verma IM (1999) Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations. Proc Natl Acad Sci USA 96:13920–13925CrossRefPubMed
20.
Zurück zum Zitat Antoniou AC, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2005) Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 42(7):602–603CrossRefPubMed Antoniou AC, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2005) Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 42(7):602–603CrossRefPubMed
Metadaten
Titel
A new mutation of BRCA2 gene in an Italian healthy woman with familial breast cancer history
verfasst von
Maurizio Pisanò
Valeria Mezzolla
Maria Maddalena Galante
Giovanni Alemanno
Corrado Manca
Vito Lorusso
Antonio Malvasi
Andrea Tinelli
Publikationsdatum
01.03.2011
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 1/2011
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-010-9389-7

Weitere Artikel der Ausgabe 1/2011

Familial Cancer 1/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.